Startup magic: Yale’s Crews describes how ideas become therapies

Yale’s Craig Crews leveraged basic science research that formed the basis of a cancer drug eventually valued at nearly $10 billion.

Yale’s Craig Crews leveraged basic science research that formed the basis of a cancer drug eventually valued at nearly $10 billion.

Now Crews, the Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of chemistry and pharmacology, and executive director of the Yale Center for Molecular Discovery at West Campus, is trying to recapture the magic again with New Haven startup Arvinas. For his efforts, he was named Connecticut Entrepreneur of the Year by CURE, the state’s premier health science organization.

In this video, Crews outlines the ingredients needed to transform an idea into a life-saving drug.

Share this with Facebook Share this with X Share this with LinkedIn Share this with Email Print this

Media Contact

Bill Hathaway: william.hathaway@yale.edu, 203-432-1322